literature

HIV mutation literature information.

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.

PMID: 23259737 2012 BMC infectious diseases

Result: It must be noted, that three of the patients with developed drug resistance were heavily experienced with reverse transcriptase (RT) and protease (PR) mutations (patient 1: RT: M41L, K103N, M184V, T215S; PR: L10I; patient 2: PR: M41L, V118I, K103N, M184V, L210W, T215S, RT: L10I,

Emerging transmitted drug resistance in treatment-naive human immunodeficiency virus-1 CRF06_cpx-infected patients in Estonia.

PMID: 20964489 2011 Scandinavian journal of infectious diseases

Abstract: A total of 2.8% of sequences harboured mutations indicating nucleoside/nucleotide reverse transcriptase inhibitor resistance (M41L, M184V, M184I, T215C and T215D), 2.1% non-nucleoside reverse transcriptase inhibitor resistance (K103N, P225H) and 2.8% protease inhibitor resistance (M46I, L90M).

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

PMID: 22132100 2011 PloS one

Method: RT mutations were identified from the International AIDS Society USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion 69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I, Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W, T215Y/F,

PMID: 20102272 2010 The Journal of infectious diseases

Method: For single-genome sequencing analyses, a total of 27 subjects (15 NNRTI-naive and 12 NNRTI-experienced) were randomly selected from enrollees meeting the following criteria: i) entry sample negative for NNRTI-resistance mutations by standard genotype analysis (ViroSeq platform; Celera, Alameda, CA); ii) reached a protocol-defined virologic failure endpoint by study week 24, and iii) the virologic failure sample had one or more major NNRTI-resistance mutations (L100I, K101E, K103N, V106A or M, V108I, Y181C or I, Y188C, H, or L, G

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

PMID: 20462946 2010 The Journal of antimicrobial chemotherapy

Method: These mutations included: (i) 46 non-polymorphic NNRTI-selected mutations at 28 positions (I94L, A98G, L100I, K101E/H/N/P, K102N, K103H/N/S/T, S105T, V106A/M, E138Q, T139R, I178F, V179F, Y181C/I/V, Y188C/H/L, G190A/C/E/Q/S, H221C/Y, K223T,

PMID: 20610954 2010 AIDS (London, England)

Abstract: Of note, the P225H and A71V are 'minor' drug-resistance mutations conferring only minimal drug-resistance phenotypes in the absence of major mutations.

Abstract: The prevalence of nonnucleoside transcriptase inhibitor mutations was 74%, with P225H present in 55% of study specimens.

Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.

PMID: 23875516 2010 Boletin de la Asociacion Medica de Puerto Rico

Result: For women, P225H was among the top ten mutations (6.6%) while in males its expression was 1.9%.

Result: Significant differences between men and women for the expression of K103N (P=0.0456) and P225H (P=0.006) were recorded.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

PMID: 19320243 2009 Antiviral therapy

Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

PMID: 19417582 2009 AIDS (London, England)

Method: NNRTI mutations included K103N, Y181C, Y181I, G190A, G190S, V108I, Y188L, V106M, P225H, and K103NS.

Result: The most frequent NNRTI mutations were Y181C (55%), G190A (30%), K103N (28%), K101E (15%), Y188L (8%), V106M (7%), Y181I (6%), K103N/S (2%),

PMID: 19545051 2009 Yao xue xue bao

Abstract: All nine recombinant VSVG/HIV-mut pseudovirions (VSVG/HIV-wt, VSVG/HIV(-K103N), VSVG/HIV(-Y181C), VSVG/HIV(-L100I,K103N), VSVG/HIV(-Y188L), VSVG/HIV(-K103N,Y181C), VSVG/HIV(-K103N,P225H), VSVG/HIV(-K103N,Y188L), VSVG/HIV(-K103N,G109A) and VSVG/HIV(-K103N,V108I)) had high efficient infectivity.

Browser Board

Co-occurred Entities

Filtrator